Table 1.
Patient Characteristics
| All Patients (n=24) | Patients with Positive Transrectal Biopsy (n=16) | Patients with Negative Transrectal Biopsy (n=8) | p Value | |
|---|---|---|---|---|
| Age1 (years), median (range) | 70.5 (48 - 82) | 74.5 (48 - 82) | 68.5 (57 - 71) | 0.062 |
| Initial PSA (ng/mL), median (range) | 6.80 (1.10 - 53.00) | 7.03 (1.10 - 53.00) | 6.70 (1.75 - 12.00) | 0.587 |
| Follow-up PSA2 (ng/mL), median (range) | 1.63 (0.43 - 6.30) | 1.47 (0.43 - 6.30) | 3.03 (0.44 - 5.50) | 0.132 |
| Time since radiation treatment (months), median (range) | 43.6 (17.0 - 113.7) | 49.3 (17.0 - 92.6) | 42.8 (17.4 - 113.7) | 1.000 |
| Initial clinical stage, n3 (%) | ||||
| 1c | 12 (52%) | 5 (33%) | 7 (88%) | 0.075 |
| 2a | 3 (13%) | 3 (20%) | 0 | |
| 2b | 1 (4%) | 1 (7%) | 0 | |
| 2c | 3 (13%) | 3 (20%) | 0 | |
| 3a | 3 (13%) | 3 (20%) | 0 | |
| 3b | 1 (4%) | 0 | 1 (12%) | |
| Initial Gleason score, n (%) | ||||
| 3+3 | 8 (33%) | 4 (25%) | 4 (50%) | 0.558 |
| 3+4 | 8 (33%) | 6 (37%) | 2 (25%) | |
| 4+3 | 5 (21%) | 3 (19%) | 2 (25%) | |
| 4+4 | 3 (13%) | 3 (19%) | 0 | |
| Neoadjuvant hormones, n (%) | ||||
| Yes | 10 (42%) | 8 (50%) | 2 (25%) | 0.388 |
| No | 14 (58%) | 8 (50%) | 6 (75%) |
Note: There were no statistically significant differences in the clinical characteristics between the two patient groups.
(1)
Age at the time of MRI.
(2)
Follow-up PSA closest to the time of MRI.
(3)
Initial clinical stage information was not available in one patient.